中华危重症医学杂志（电子版）
中華危重癥醫學雜誌（電子版）
중화위중증의학잡지（전자판）
CHINESE JOURNAL OF CRITICAL CARE MEDICINE ( ELECTRONIC EDITON)
2015年
3期
165-168
,共4页
通心络%糖尿病,2型%内皮素-1%超敏C反应蛋白
通心絡%糖尿病,2型%內皮素-1%超敏C反應蛋白
통심락%당뇨병,2형%내피소-1%초민C반응단백
Tongxinluo%Diabetes mellitus,type 2%Endothelin-1%High sensitivity C-reactive protein
目的：研究通心络对2型糖尿病（T2DM）患者血管内皮功能和炎症反应的干预作用。方法选取2013年1月至2014年3月期间在绍兴文理学院附属医院和浙江大学医学院附属第一医院诊治的T2DM患者80例，分为通心络治疗组和对照组，各40例。于治疗前与治疗后8周分别测定两组患者的糖化血红蛋白（HbA1C）、内皮素-1和超敏C反应蛋白（hs-CRP）。结果治疗后8周，对照组与通心络治疗组患者HbA1C差异无统计学意义[（5.7±1.0）% vs.（5.9±1.0）%，t=0.639，P>0.05]，通心络组患者内皮素-1和hs-CRP均明显低于对照组[（74±9）ng/L vs.（79±10）ng/L，（4.1±1.9）mg/L vs.（6.1±3.0）mg/L；t=2.743，3.709；P均<0.05]。通心络组患者的内皮素-1与 hs-CRP 较治疗前降低[（74±9）ng / L vs.（80±11）ng / L，（4.1±1.9）mg/L vs.（6.4±3.4）mg/L；t=2.875，3.704；P均<0.05]，而对照组含量较治疗前均无明显变化[（79±10）ng/L vs.（80±10）ng/L，（6.1±3.0）mg/L vs.（6.1±3.1） mg/L；t =0.182，0.368；P均>0.05]。结论通心络可能有助于改善T2DM患者的血管内皮功能和炎症反应情况。
目的：研究通心絡對2型糖尿病（T2DM）患者血管內皮功能和炎癥反應的榦預作用。方法選取2013年1月至2014年3月期間在紹興文理學院附屬醫院和浙江大學醫學院附屬第一醫院診治的T2DM患者80例，分為通心絡治療組和對照組，各40例。于治療前與治療後8週分彆測定兩組患者的糖化血紅蛋白（HbA1C）、內皮素-1和超敏C反應蛋白（hs-CRP）。結果治療後8週，對照組與通心絡治療組患者HbA1C差異無統計學意義[（5.7±1.0）% vs.（5.9±1.0）%，t=0.639，P>0.05]，通心絡組患者內皮素-1和hs-CRP均明顯低于對照組[（74±9）ng/L vs.（79±10）ng/L，（4.1±1.9）mg/L vs.（6.1±3.0）mg/L；t=2.743，3.709；P均<0.05]。通心絡組患者的內皮素-1與 hs-CRP 較治療前降低[（74±9）ng / L vs.（80±11）ng / L，（4.1±1.9）mg/L vs.（6.4±3.4）mg/L；t=2.875，3.704；P均<0.05]，而對照組含量較治療前均無明顯變化[（79±10）ng/L vs.（80±10）ng/L，（6.1±3.0）mg/L vs.（6.1±3.1） mg/L；t =0.182，0.368；P均>0.05]。結論通心絡可能有助于改善T2DM患者的血管內皮功能和炎癥反應情況。
목적：연구통심락대2형당뇨병（T2DM）환자혈관내피공능화염증반응적간예작용。방법선취2013년1월지2014년3월기간재소흥문이학원부속의원화절강대학의학원부속제일의원진치적T2DM환자80례，분위통심락치료조화대조조，각40례。우치료전여치료후8주분별측정량조환자적당화혈홍단백（HbA1C）、내피소-1화초민C반응단백（hs-CRP）。결과치료후8주，대조조여통심락치료조환자HbA1C차이무통계학의의[（5.7±1.0）% vs.（5.9±1.0）%，t=0.639，P>0.05]，통심락조환자내피소-1화hs-CRP균명현저우대조조[（74±9）ng/L vs.（79±10）ng/L，（4.1±1.9）mg/L vs.（6.1±3.0）mg/L；t=2.743，3.709；P균<0.05]。통심락조환자적내피소-1여 hs-CRP 교치료전강저[（74±9）ng / L vs.（80±11）ng / L，（4.1±1.9）mg/L vs.（6.4±3.4）mg/L；t=2.875，3.704；P균<0.05]，이대조조함량교치료전균무명현변화[（79±10）ng/L vs.（80±10）ng/L，（6.1±3.0）mg/L vs.（6.1±3.1） mg/L；t =0.182，0.368；P균>0.05]。결론통심락가능유조우개선T2DM환자적혈관내피공능화염증반응정황。
Objective To investigate the intervention effect of Tongxinluo on vascular endothelial function and inflammatory reaction in patients with type 2 diabetes. Methods A total of 80 patients with type 2 diabetes hospitalized in the Affiliated Hospital of Shaoxing University and the First Affiliated Hospital, Zhejiang University School of Medicine from January 2013 to March 2014 were enrolled into the study. They were divided into the Tongxinluo group and the control group, 40 cases in each group. The levels of glycosylated hemoglobin (HbA1C), endothelin-1, high sensitivity C-reactive protein (hs-CRP) in the two groups were determined before and after 8 weeks of the Tongxinluo therapy. Results There were no statistical differences in the HbA1C levels between the control group and Tongxinluo group after eight-week Tongxinluo therapy [(5.7 ± 1.0)% vs. (5.9 ± 1.0)%, t=0.639, P>0.05]. Compared with the control group, the levels of endothelin-1 and hs-CRP of patients in the Tongxinluo group were remarkably lower [(74 ± 9) ng/L vs. (79 ± 10) ng/L, (4.1 ± 1.9) mg/L vs. (6.1 ± 3.0) mg/L; t=2.743, t = 3.709; all P < 0.05]; they were obviously lower after 8 weeks therapy than those before the Tongxinluo therapy [(74 ± 9)ng/L vs.(80 ± 11)ng/L,(4.1 ± 1.9)mg/L vs.(6.4 ± 3.4)mg/L;t=2.875, 3.704; all P<0.05]; while in the control group, no statistical differences were noted in the levels of endothelin-1 and hs-CRP between before and after 8 weeks of Tongxinluo therapy [(79 ± 10) ng/L vs. (80 ± 10) ng/L, (6.1 ± 3.0) mg/L vs. (6.1 ± 3.1) mg/L; t = 0.182, 0.368;all P > 0.05]. Conclusion Tongxinluo can improve the vascular endothelial function and inflammatory reaction in patients with type 2 diabetes.
